Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. (ESPR) Stock Overview
Explore Esperion Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
542.6M
P/E Ratio
-27.23
EPS (TTM)
$-0.11
ROE
0.06%
ESPR Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Esperion Therapeutics, Inc. (ESPR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 42.46, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $3.91.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -27.23 and a market capitalization of 542.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.